The decade of polyomavirus BK-associated nephropathy: State of affairs

Transplantation

Volumn 87, Issue 5, 2009, Pages 621-630

  Ramos, Emilio ^a,e   Drachenberg, Cinthia B ^b   Wali, Ravinder ^a   Hirsch, Hans H ^c,d  

^a SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Early diagnosis; Graft loss; Histologic patterns; JC; Nephritis; Renal biopsy; Renal transplant; SV40; Viral loads; Viremia; Viruria

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CIDOFOVIR; CORTICOSTEROID; IMMUNOGLOBULIN; INTERFERON; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS;

BK VIRUS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; JC VIRUS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; REVIEW; RISK FACTOR; URINE CYTOLOGY; VIRUS INFECTION; VIRUS SHEDDING; CHILD; DIFFERENTIAL DIAGNOSIS; ISOLATION AND PURIFICATION; PATHOLOGY; URINE; VIROLOGY;

BK VIRUS; CHILD; DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY TRANSPLANTATION; POLYOMAVIRUS INFECTIONS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; URINE;

EID: 65649142921     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318197c17d     Document Type: Review

References (87)

1. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A paired donor kidney analysis. Transplantation 2002; 74: 1377.
2. Russell RT, Feurer ID, Wisawatapnimit P, et al. The effects of physical quality of life, time, and gender on change in symptoms of anxiety and depression after liver transplantation. J Gastrointest Surg 2008; 12: 138.
3. Sundaram SS, Landgraf JM, Neighbors K, et al. Adolescent health-related quality of life following liver and kidney transplantation. Am J Transplant 2007; 7: 982.
4. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the united states, 1988 to 1996. N Engl J Med 2000; 342: 605.
5. Tantravahi J, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med 2007; 58: 369.
6. Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients - An analysis of USRDS data. Am J Transplant 2007; 7: 653.
7. Dharnidharka VR, Caillard S, Agodoa LY, et al. Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 2006; 81: 1662.
8. Egli A, Binggeli S, Bodaghi S, et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007; 22(suppl 8): viii72.
9. Hirsch HH. Polyomavirus BK nephropathy: A (re-) emerging complication in renal transplantation. Am J Transplant 2002; 2: 25.
10. Ramos E, Drachenberg CB, Portocarrero M, et al. BK virus nephropathy diagnosis and treatment: Experience at the University of Maryland Renal Transplant Program. Clin Transpl 2002: 143.
11. Ramos E, Hirsch HH. Polyomavirus-associated nephropathy: Updates on a persisting challenge. Transpl Infect Dis 2006; 8: 59.
12. Mackenzie EF, Poulding JM, Harrison PR, et al. Human polyoma virus (HPV) - A significant pathogen in renal transplantation. Proc Eur Dial Transplant Assoc 1978; 15: 352.
13. Purighalla R, Shapiro R, McCauley J, et al. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 1995; 26: 671.
14. Binet I, Nickeleit V, Hirsch HH, et al. Polyomavirus disease under new immunosuppressive drugs: A cause of renal graft dysfunction and graft loss. Transplantation 1999; 67: 918.
15. Drachenberg CB, Beskow CO, Cangro CB, et al. Human polyoma virus in renal allograft biopsies: Morphological findings and correlation with urine cytology. Hum Pathol 1999; 30: 970.
16. Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67: 103.
17. Howell DN, Smith SR, Butterly DW, et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999; 68: 1279.
18. Mathur VS, Olson JL, Darragh TM, et al. Polyomavirus-induced interstitial nephritis in two renal transplant recipients: Case reports and review of the literature. Am J Kidney Dis 1997; 29: 754.
19. Polo C, Perez JL, Mielnichuck A, et al. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect 2004; 10: 640.
20. Drachenberg CB, Hirsch HH, Ramos E, et al. Polyomavirus disease in renal transplantation: Review of Pathological findings and diagnostic methods. Hum Pathol 2005; 36: 1245.
21. Drachenberg CB, Hirsch HH, Papadimitriou JC, et al. Cost efficiency in the prospective diagnosis and follow-up of polyomavirus allograft nephropathy. Transplant Proc 2004; 36: 3028.
22. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.
23. Gardner SD, Field AM, Coleman DV, et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971; 1: 1253.
24. Knowles WA, Pillay D, Johnson MA, et al. Prevalence of long-term BK and JC excretion in HIV-infected adults and lack of correlation with serological markers. J Med Virol 1999; 59: 474.
25. Shah KV, Daniel RW, Warszawski RM. High prevalence of antibodies to BK virus, an SV40-related papovavirus, in residents of Maryland. J Infect Dis 1973; 128: 784.
26. Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84: 1499.
27. Randhawa PS, Gupta G, Vats A, et al. Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol 2006; 13: 1057.
28. Andrews C, Shah KV, Rubin R, et al. BK papovavirus infections in renal transplant recipients: Contribution of donor kidneys. J Infect Dis 1982; 145: 276.
29. Andrews CA, Shah KV, Daniel RW, et al. A serological investigation of BK virus and JC virus infections in recipients of renal allografts. J Infect Dis 1988; 158: 176.
30. Gardner SD, MacKenzie EF, Smith C, et al. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol 1984; 37: 578.
31. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488.
32. Bohl DL, Storch GA, Ryschkewitsch C, et al. Donor origin of BK virus in renal transplantation and role of hla c7 in susceptibility to sustained BK viremia. Am J Transplant 2005; 5: 2213.
33. Comoli P, Azzi A, Maccario R, et al. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 2004; 78: 1229.
34. Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7: 2727.
35. Comoli P, Binggeli S, Ginevri F, et al. Polyomavirus-associated nephropathy: Update on BK virus-specific immunity. Transpl Infect Dis 2006; 8: 86.
36. Zhou W, Sharma M, Martinez J, et al. Functional characterization of BK virus-specific cd4(+) t cells with cytotoxic potential in seropositive adults. Viral Immunol 2007; 20: 379.
37. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145.
38. Drachenberg CB, Hirsch HH, Papadimitriou JC, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: A prospective evaluation. Transplantation 2007; 84: 323.
39. Hirsch HH, Friman S, Wiecek A, et al. Prospective study of polyomavirus BK viruria and viremia in de novo renal transplantation. Am J Transplant 2007; 7: 150.
40. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582.
41. White LH, Casian A, Hilton R, et al. BK virus nephropathy in renal transplant patients in London. Transplantation 2008; 85: 1008.
42. Krymskaya L, Sharma MC, Martinez J, et al. Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol 2005; 79: 11170.
43. *02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals. Virology 2006; 350: 128.
44. Randhawa P, Zygmunt D, Shapiro R, et al. Viral regulatory region sequence variations in kidney tissue obtained from patients with BK virus nephropathy. 2003; 64: 743.
45. Randhawa PS, Khaleel-Ur-Rehman K, Swalsky PA, et al. DNA sequencing of viral capsid protein VP-1 region in patients with BK virus interstitial nephritis. Transplantation 2002; 73: 1090.
46. Gosert R, Rinaldo CH, Funk GA, et al. Polyomavirus BK with rear-ranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008; 205: 841.
47. Binggeli S, Egli A, Dickenmann M, et al. BKV replication and cellular immune responses in renal transplant recipients. Am J Transplant 2006; 6: 2218.
48. Binggeli S, Egli A, Schaub S, et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 2007; 7: 1131.
49. Sharma PM, Gupta G, Vats A, et al. Phylogenetic analysis of polyomavirus BK sequences. J Virol 2006; 80: 8869.
50. Chen Y, Trofe J, Gordon J, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 2006; 80: 3495.
51. Trofe J, Hirsch HH, Ramos E. Polyomavirus-associated nephropathy: Update of clinical management in kidney transplant patients. Transpl Infect Dis 2006; 8: 76.
52. Trofe J, Chaudhury P, Gordon J, et al. Early steroid cessation-avoidance regimens are associated with a lower incidence of polyomavirus nephropathy compared with steroid-based immunosuppression in kidney transplant recipients. Transplant Rev 2003; 17: S52.
53. Cheeseman SH, Black PH, Rubin RH, et al. Interferon and BK papovavirus - Clinical and laboratory studies. J Infect Dis 1980; 141: 157.
54. Leuenberger D, Andresen PA, Gosert R, et al. Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. Clin Vaccine Immunol 2007; 14: 959.
55. Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: Correlation with graft outcome and viral load. Am J Transplant 2004; 4: 2082.
56. Meehan SM, Kadambi PV, Manaligod JR, et al. Polyoma virus infection of renal allografts: Relationships of the distribution of viral infection, tubulointerstitial inflammation, and fibrosis suggesting viral interstitial nephritis in untreated disease. Hum Pathol 2005; 36: 1256.
57. Nickeleit V, Singh HK, Mihatsch JM. Latent and productive polyomavirus infections of renal allografts: Morphological, clinical, and pathophysiological aspects. Adv Exp Med Biol 2006; 577: 190.
58. Mannon RB, Hoffmann SC, Kampen RL, et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant 2005; 5: 2883.
59. Randhawa P, Uhrmacher J, Pasculle W, et al. A comparative study of BK and JC virus infections in organ transplant recipients. J Med Virol 2005; 77: 238.
60. Bansal S, Lucia MS, Wiseman A. A case of polyomavirus-associated nephropathy presenting late after transplantation. Nat Clin Pract Nephrol 2008; 4: 283.
61. Funk, GA, Steiger, J, Hirsch, HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis 2006; 193: 80.
62. Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008; 85: 850.
63. Lipshutz GS, Mahanty H, Feng S, et al. BKV in simultaneous pancreas-kidney transplant recipients: A leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant 2005; 5: 366.
64. Singh B, Kiberd B, Gupta R, et al. Polyoma virus-induced hemorrhagic cystitis in renal transplantation patient with polyomavirus nephritis. Urology 2006; 67: 432. e11.
65. Ramos E, Vincenti F, Lu WX, et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation 2004; 77: 131.
66. Hirsch HH, Ramos E. Retransplantation after polyomavirus-associated nephropathy: Just do it? Am J Transplant 2006; 6: 7.
67. Kausman JY, Somers GR, Francis DM, et al. Association of renal adenocarcinoma and BK virus nephropathy post transplantation. Pediatr Nephrol 2004; 19: 459.
68. Narayanan M, Szymanski J, Slavcheva E, et al. BK virus associated renal cell carcinoma: Case presentation with optimized PCR and other diagnostic tests. Am J Transpl 2007; 7: 1666.
69. Emerson LL, Carney HM, Layfield LJ, et al. Collecting duct carcinoma arising in association with BK nephropathy post-trasnplantation in a pediatric patient. A case report with immunohistochemical and in situ hybridization study. Pediatr Transpl 2008; 12: 600.
70. Duvuru G, Tong BC, Racusen L, et al. Bladder carcinoma in a transplant recipient: Evidence to implicate the BK human polyomavirus as a causal transforming agent. Transplantation 2002; 73: 1933.
71. Tognon M, Corallini A, Martini F, et al. Oncogenic transformation by BK virus and association with human tumors. Oncogene 2003; 22: 5192.
72. Caracciolo V, Reiss K, Khalili K, et al. Role of the interaction between large T antigen and Rb family members in the oncogenicity of JC virus. Oncogene 2006; 25: 5294.
73. Weinreb DB, Desman GT, Burstein DE, et al. Expression of p53 in virally infected tubular cells in renal transplant patients with polyomavirus nephropathy. Hum Pathol 2006; 37: 684.
74. Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: Evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 2006; 10: 920.
75. Rinaldo CH, Hirsch HH. Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti Infect Ther 2007; 5: 105.
76. Vats A, Shapiro R, Singh Randhawa P, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003; 75: 105.
77. Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005; 5: 1997.
78. Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007; 20: 962.
79. Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006; 81: 704.
80. Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: One-year follow-up of renal allograft recipients. Transplantation 2006; 81: 117.
81. Wadei HM, Rule AD, Lewin M, et al. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant 2006; 6: 1025.
82. Cosio FG, Am H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies. Transplantation 2007; 83: 411.
83. Wali RK, Drachenberg C, Hirsch H, et al. Intensive versus routine care screening for polyoma viral replication (cluster randomization) and a road map for stepwise modification of immunosuppression therapy. Am J Transplant 2008; 8(suppl 2): 283.
84. Farasati NA, Shapiro R, Vats A, et al. Effect of leflunomide and cidofovir on replication of BK-virus in an in vitro culture system. Transplantation 2005; 79: 116.
85. Atwood W, Jordan J, Sadhu M, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006; 81:704.
86. Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005; 352: 1157.
87. Ali SH, Chandraker A, DeCaprio JA. Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther 2007; 12: 1.